Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Depreciation and Depletion (2016 - 2025)

Capricor Therapeutics (CAPR) has 11 years of Depreciation and Depletion data on record, last reported at $494726.0 in Q3 2025.

  • For Q3 2025, Depreciation and Depletion rose 36.98% year-over-year to $494726.0; the TTM value through Sep 2025 reached $1.8 million, up 29.85%, while the annual FY2024 figure was $1.4 million, 33.34% up from the prior year.
  • Depreciation and Depletion reached $494726.0 in Q3 2025 per CAPR's latest filing, up from $486278.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $494726.0 in Q3 2025 and bottomed at $49054.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $245116.4, with a median of $254702.0 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: surged 148.78% in 2023, then rose 22.14% in 2024.
  • A 5-year view of Depreciation and Depletion shows it stood at $78645.0 in 2021, then surged by 143.63% to $191602.0 in 2022, then soared by 60.55% to $307608.0 in 2023, then increased by 22.14% to $375705.0 in 2024, then skyrocketed by 31.68% to $494726.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $494726.0 in Q3 2025, $486278.0 in Q2 2025, and $405450.0 in Q1 2025.